First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial
Ki Hyeong Lee(Chungbuk National University Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Chong‐Jen Yu(National Taiwan University Hospital), Takako Inoue(Osaka International Cancer Institute), Cheng‐Ta Yang(Shanghai Medical College of Fudan University), Nobuyuki Yamamoto(Wakayama Medical University), Hye Ryun Kim(Yonsei University), Makoto Nishio(Japanese Foundation For Cancer Research), Shunichi Sugawara(Sendai Kousei Hospital), Hiroaki Akamatsu(Army Medical University), Toyoaki Hida(Saitama International Medical Center), Tatsuya Yoshida(Juntendo University), Yuichiro Ohe(National Cancer Center), Hiroshi Tanaka(Tokyo Medical and Dental University), Tomohide Tamura(St. Luke's International Hospital), Jin Hyoung Kang(The Catholic University of Korea Seoul St. Mary's Hospital), Naoki Inui(Hamamatsu University School of Medicine), Shigeru Takahashi(Ono Pharmaceutical (Japan)), Jong Seok Lee(Brigham and Women's Hospital)
Cited by 9
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k